NEJM Evididence
Avapritinib versus placebo in indolent systemic mastocytosis.
Gotlib J, Castells M, Elberink HO, et al.
Results from this randomized trial demonstrate superior reduction of uncontrolled symptoms and mast cell burden in patients with moderate to severe indolent systemic mastocytosis treated with avapritinib versus placebo. Option 2: Learn about the superiority of avapritinib versus placebo in moderate to severe indolent systemic mastocytosis.
Previous Article
- • Comparison between indolent systemic mastocytosis and clonal mast cell disease not meeting WHO diagnostic criteria: a nationwide multicenter retrospective analysis.
- • Standardized indolent systemic mastocytosis evaluations across a health care system: implications for screening accuracy
- • Plasma protein profiling to discern indolent from advanced systemic mastocytosis
- • Indolent systemic mastocytosis (ISM) without skin lesions as a recurrent anaphylaxis: a case report study.
- • Safety of a mRNA COVID-19 vaccine in patients with indolent systemic mastocytosis.
- • Avapritinib versus placebo in indolent systemic mastocytosis.
- • The influence of nutritional habits, body mass index and intestinal microbiota in mastocytosis on clinical symptoms using conventional culture and next generation sequencing.
- • Genome-wide DNA methylation and gene expression in patients with indolent systemic mastocytosis.
- • Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.
- • Indolent systemic mastocytosis and aleukemic mast cell leukemia: Subtle diagnostic differences with distinct management approaches.
- • Psychometric evaluation of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF©) and determination of a threshold score for moderate symptoms.
- • The international consensus classification of mastocytosis and related entities.
- • The Mastocytosis Control Test for Assessing Disease Control
- • The Validated Mastocytosis Control Test for Measuring Disease Control
